Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: Possible relevance to neuroprotective interventions in schizophrenia

Synapse

Volumn 62, Issue 11, 2008, Pages 804-818

  Yang, Tsung Tsair ^a,b   Wang, Su Jane ^a  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

Author keywords

Atypical antipsychotic; Glutamate; PKA; Prefrontal cortex; Schizophrenia; Synaptosomes

Indexed keywords

4 AMINOPYRIDINE; ARIPIPRAZOLE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CALCIUM ION; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; GLUTAMIC ACID; HALOPERIDOL; IONOMYCIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; OPC 14857; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL MEMBRANE DEPOLARIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; IN VITRO STUDY; MALE; NERVE EXCITABILITY; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SODIUM TRANSPORT; SYNAPTIC MEMBRANE; SYNAPTOSOME;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PIPERAZINES; PREFRONTAL CORTEX; PRESYNAPTIC TERMINALS; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 52249098573     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20548     Document Type: Article

References (46)

1. 2(5). J Neurochem 48:552-559.
2. Barrie AP, Nicholls DG, Sanchez-Prieto J, Sihra TS. 1991. An ion channel locus for the protein kinase C potentiation of transmitter glutamate release from guinea pig cerebrocortical synaptosomes. J Neurochem 57:1398-1404.
3. Berman KF, Weinberger DR. 1990. The prefrontal cortex in schizophrenia and other neuropsychiatric diseases: In vivo physiological correlates of cognitive deficits. Prog Brain Res 85:521-536.
4. Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA. 1985. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry 147:276-282.
5. Bliss TV, Collingridge GL. 1993. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 361:31-39.
6. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F. 2007. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl) 191:745-758.
7. Bruins Slot LA, De Vries L, Newman-Tancredi A, Cussac D. 2006. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 534:63-70.
8. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. 2002. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389.
9. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A. 2005. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res 1043:32-41.
10. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. 2001. A revised excitotoxic hypothesis of schizophrenia: Therapeutic implications. Clin Neuropharmacol 24:43-49.
11. Eren I, Naziroglu M, Demirdas A. 2007. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem Res 32:1188-1195.
12. 2+/calmodulin- and cAMP-dependent protein kinases in vitro. J Neurosci 15:2385-2395.
13. Goff DC, Coyle JT. 2001. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367-1377.
14. Greengard P, Valtorta F, Czernik AJ, Benfenati F. 1993. Synaptic vesicle phosphoproteins and regulation of synaptic function. Science 259:780-785.
15. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450.
16. Heusler P, Newman-Tancredi A, Castro-Fernandez A, Cussac D. 2007. Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. Neuropharmacology 52:1106-1113.
17. Jentsch JD, Roth RH. 1999. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
18. Kline AE, Yu J, Horvath E, Marion DW. 2001. The selective 5-HT1A receptor agonist repinotan HCL attenuates histopathology and spatial learning deficits following traumatic brain injury in rats. Neuroscience 106:547-555.
19. Kristensen JD, Svensson B, Gordh T Jr. 1992. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans. Pain 51:249-253.
20. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB. 1999. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627.
21. Lonart G, Janz R, Johnson KM, Sudhof TC. 1998. Mechanism of action of rab3A in mossy fiber LTP. Neuron 21:1141-1150.
22. Macciardi F, Lucca A, Catalano M, Marino C, Zanardi R, Smeraldi E. 1990. Amino acid patterns in schizophrenia: Some new findings. Psychiatry Res 32:63-70.
23. Mauler F, Fahrig T, Horvath E, Jork R. 2001. Inhibition of evoked glutamate release by the neuroprotective 5-HT1A receptor agonist BAY 3702 in vitro and in vivo. Brain Res 888:150-157.
24. McMahon HT, Nicholls DG. 1991. The bioenergetics of neurotransmitter release. Biochim Biophys Acta 1059:243-264.
25. Meador-Woodruff JH, Healy DJ. 2000. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 31:288-294.
26. Nichollls DG. 1989. Release of glutamate, aspartate, and gamma-aminobutyric acid from isolated nerve terminals. J Neurochem 52:331-341.
27. Nicholls DG. 1993. The glutamatergic nerve terminal. Eur J Biochem 212:613-631.
28. Nicholls DG. 1998. Presynaptic modulation of glutamate release. Prog Brain Res 116:15-22.
29. Nicholls DG, Sihra TS, Sanchez-Prieto J. 1987. The role of the plasma membrane and intracellular organelles in synaptosomal calcium regulation. Soc Gen Physiol Ser 42:31-43.
30. Olney JW, Farber NB. 1995. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
31. Oosterink BJ, Korte SM, Nyakas C, Korf J, Luiten PGM. 1998. Neuroprotection against N-methyl-D-aspartate-induced excitotoxicity in rat magnocellular nucleus basalis by the 5-AH1A receptor agonist 8-OH-DPAT. Eur J Pharmacol 358:147-152.
32. Risinger C, Bennett MK. 1999. Differential phosphorylation of syntaxin and synaptosome-associated protein of 25 kDa (SNAP-25) isoforms. J Neurochem 72:614-624.
33. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. 2003. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
34. 2+ entry preferentially effects protein dephosphorylation, phosphorylation, and glutamate release. J Biol Chem 267:1983-1989.
35. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry KT, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD. 2007. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: Functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 190:373-382.
36. 2+ and glutamate release. J Neurochem 53:1693-1699.
37. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT. 1995. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52:829-836.
38. Turner TJ, Dunlap K. 1995. Pharmacological characterization of presynaptic calcium channels using subsecond biochemical measurements of synaptosomal neurosecretion. Neuropharmacology 34:1469-1478.
39. Urban JD, Vargas GA, von Zastrow M, Mailman RB. 2007. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32:67-77.
40. Vazquez E, Sanchez-Prieto J. 1997. Presynaptic modulation of glutamate release targets different calcium channels in rat cerebrocortical nerve terminals. Eur J Neurosci 9:2009-2018.
41. Wang SJ, Yang TT. 2005. Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders. Drug News Perspect 18:561-566.
42. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A. 2006. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol 546:88-94.
43. Wroblewski JT, Danysz W. 1989. Modulation of glutamate receptors: Molecular mechanisms and functional implications. Annu Rev Pharmacol Toxicol 29:441-474.
44. Yang TT, Wang SJ. 2005. Effects of haloperidol and clozapine on glutamate release from nerve terminals isolated from rat prefrontal cortex. Synapse 56:12-20.
45. Yulug B, Yildiz A, Hudaoglu O, Kilic E, Cam E, Schabitz WR. 2006. Olanzapine attenuates brain damage after focal cerebral ischemia in vivo. Brain Res Bull 71:296-300.
46. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J. 2006. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 71:521-529.